Walmart launching its own low-cost insulin to ‘revolutionize’ affordability for diabetics

Brett Molina

Walmart will launch its own brand of insulin, which the retailing giant says will “revolutionize the access and affordability” of diabetes treatments.

In a statement Tuesday, Walmart said it will offer analog insulin vials and FlexPens for administering doses through its ReliOn brand.

The retailer claims its insulin options will save customers between 58% to 75% compared to branded products.

“We know many people with diabetes struggle to manage the financial burden of this condition, and we are focused on helping by providing affordable solutions,” said Dr. Cheryl Pegus, executive vice president, Walmart Health & Wellness, in a statement.

The ReliOn products will be available this week at Walmart pharmacies and launch in Sam’s Club pharmacies next month.

The lower-cost insulin is being released by Walmart in response to surging costs for the treatment used for patients with diabetes. According to the Health Care Cost Institute, a non-profit organization that sheds light on health care spending, the average price for an insulin prescription nearly doubled from 2012 ($344) to 2016 ($666).

Tracey D. Brown, chief executive officer of the American Diabetes Association, said in a statement Tuesday medical costs for treating diabetes are estimated at around $9,601 per person annually.

“We welcome all affordable solutions that make diabetes management more accessible to millions of Americans living with diabetes,” said Brown.